Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer

Goldhirsch, 2005, Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005, Ann Oncol, 16, 1569, 10.1093/annonc/mdi326 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable her2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Joensuu, 2006, Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer, N Engl J Med, 354, 809, 10.1056/NEJMoa053028 Robert, 2006, Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer, J Clin Oncol, 24, 2786, 10.1200/JCO.2005.04.1764 Smith, 2007, 2-year follow-up of trastuzumab after adjuvant chemotherapy in her2-positive breast cancer: a randomised controlled trial, Lancet, 369, 29, 10.1016/S0140-6736(07)60028-2 Bird, 2008, Cardiac toxicity in breast cancer survivors: review of potential cardiac problems, Clin Cancer Res, 14, 14, 10.1158/1078-0432.CCR-07-1033 Dowsett, 2003, Correlation between immunohistochemistry (herceptest) and fluorescence in situ hybridization (fish) for her-2 in 426 breast carcinomas from 37 centres, J Pathol, 199, 418, 10.1002/path.1313 Yaziji, 2004, Her-2 testing in breast cancer using parallel tissue-based methods, JAMA, 291, 1972, 10.1001/jama.291.16.1972 Press, 2002, Evaluation of her-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens, J Clin Oncol, 20, 3095, 10.1200/JCO.2002.09.094 Wolff, 2007, American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, Arch Pathol Lab Med, 131, 18, 10.5858/2007-131-18-ASOCCO Lebeau, 2001, Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization, J Clin Oncol, 19, 354, 10.1200/JCO.2001.19.2.354 Fornier, 2002, Her2 testing and correlation with efficacy of trastuzumab therapy, Oncology (Williston Park), 16, 1340 Bartlett, 2001, Evaluating her2 amplification and overexpression in breast cancer, J Pathol, 195, 422, 10.1002/path.971 Gancberg, 2002, Evaluation of her-2/neu protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of her-2/neu testing, Breast Cancer Res Treat, 74, 113, 10.1023/A:1016146130767 Thomson, 2001, Her-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization, Mod Pathol, 14, 1079, 10.1038/modpathol.3880440 Tsuda, 2002, Evaluation of interobserver agreement in scoring immunohistochemical results of her-2/neu (c-erbb-2) expression detected by herceptest, nichirei polyclonal antibody, cb11 and tab250 in breast carcinoma, Pathol Int, 52, 126, 10.1046/j.1440-1827.2002.01327.x Gouvêa, 2006, Selecting antibodies to detect her2 overexpression by immunohistochemistry in invasive mammary carcinomas, Appl Immunohistochem Mol Morphol, 14, 103, 10.1097/01.pai.0000155794.64525.11 Rossi, 2005, Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies, Am J Clin Pathol, 124, 295, 10.1309/NR8HN08GDPVEMU08 Kononen, 1998, Tissue microarrays for high-throughput molecular profiling of tumor specimens, Nat Med, 4, 844, 10.1038/nm0798-844 Camp, 2000, Validation of tissue microarray technology in breast carcinoma, Lab Invest, 80, 1943, 10.1038/labinvest.3780204 Press, 2005, Diagnostic evaluation of her-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials, Clin Cancer Res, 11, 6598, 10.1158/1078-0432.CCR-05-0636 Dybdal, 2005, Determination of her2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab, Breast Cancer Res Treat, 93, 3, 10.1007/s10549-004-6275-8 Bartlett, 2004, Fluorescence in situ hybridization: technical overview, Methods Mol Med, 97, 77 Lambros, 2007, Chromogenic and fluorescent in situ hybridization in breast cancer, Hum Pathol, 38, 1105, 10.1016/j.humpath.2007.04.011 van de Vijver, 2007, Chromogenic in situ hybridisation for the assessment of her2 status in breast cancer: an international validation ring study, Breast Cancer Res, 9, R68, 10.1186/bcr1776 Landis, 1977, The measurement of observer agreement for categorical data, Biometrics, 33, 159, 10.2307/2529310 Powell, 2007, A new rabbit monoclonal antibody (4b5) for the immunohistochemical (ihc) determination of the her2 status in breast cancer: comparison with cb11, fluorescence in situ hybridization (fish), and interlaboratory reproducibility, Appl Immunohistochem Mol Morphol, 15, 94, 10.1097/PAI.0b013e31802ced25 Dendukuri, 2007, Testing for her2-positive breast cancer: a systematic review and cost-effectiveness analysis, CMAJ, 176, 1429, 10.1503/cmaj.061011 Egervari, 2008, Immunohistochemical antibodies in breast cancer her2 diagnostics. a comparative immunohistochemical and fluorescence in situ hybridization study, Tumour Biol, 29, 18, 10.1159/000132567 Kakar, 2000, Her-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival, Mol Diagn, 5, 199, 10.1007/BF03262077 Ricardo, 2007, Her2 evaluation using the novel rabbit monoclonal antibody sp3 and cish in tissue microarrays of invasive breast carcinomas, J Clin Pathol, 60, 1001, 10.1136/jcp.2006.040287